Contrasting Trimedyne (OTCMKTS:TMED) & Nexalin Technology (NASDAQ:NXL)

Nexalin Technology (NASDAQ:NXL) and Trimedyne (OTCMKTS:TMED) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Nexalin Technology and Trimedyne”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$110,000.00	365.84	-$4.65 million	($0.72)	-5.28
Trimedyne	N/A	N/A	N/A	N/A	N/A

Trimedyne has lower revenue, but higher earnings than Nexalin Technology.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Nexalin Technology and Trimedyne, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	0	1	0	3.00
Trimedyne	0	0	0	0	0.00

Nexalin Technology presently has a consensus target price of $3.00, indicating a potential downside of 21.05%. Given Nexalin Technology’s stronger consensus rating and higher possible upside, analysts plainly believe Nexalin Technology is more favorable than Trimedyne.

Profitability

This table compares Nexalin Technology and Trimedyne’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,578.81%	-213.51%	-173.41%
Trimedyne	N/A	N/A	N/A

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by company insiders. Comparatively, 11.1% of Trimedyne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nexalin Technology beats Trimedyne on 6 of the 9 factors compared between the two stocks.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Trimedyne

Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. In addition, it engages in the provision of services, and rental of lasers and other medical equipment to hospitals and surgery centers on a fee-per-case basis. The company operates in Asia, Europe, Latin America, the Middle East, Australia, and internationally. It markets its products through commission sales representatives in the United States and independent distributors internationally. Trimedyne, Inc. was founded in 1980 and is based in Irvine, California.